Supplementary Methods

Demographic and clinical data from the baseline in-lab sample are presented in Supplementary Table 1. We observed no statistically significant differences between our groups in terms of age, sex, and smartphone use.

**Supplementary Table 1.** *Demographic and Clinical Data in Schizophrenia and Control Groups from the baseline in-lab sample.*
|                                | Schizophrenia Group \(N = 26\) | Control Group \(N = 34\) | \(p\)-value |
|--------------------------------|-------------------------------|--------------------------|-------------|
| Age (years)                    |                               |                          | .10         |
| Mean \((SD)\)                  | 37.2 (11.5)                   | 32.3 (11.3)              |             |
| Median [Min, Max]              | 36.0 [20.0, 64.0]             | 29.0 [18.0, 59.0]        |             |
| Sex                            |                               |                          | .13         |
| Male                           | 21.0 (80.8 %)                 | 20.0 (58.8 %)            |             |
| Female                         | 5.0 (19.2 %)                  | 14.0 (41.2 %)            |             |
| Smartphone Use                 |                               |                          | .85         |
| Every day of the week          | 25.0 (96.4%)                  | 33.0 (97.1 %)            |             |
| 6 or less days per week        | 1.0 (3.6%)                    | 1.0 (2.9 %)              |             |
| PANSS Positive Score           |                               |                          |             |
| Mean \((SD)\)                  | 15.1 (5.4)                    |                          |             |
| Median [Min, Max]              | 15.0 [7.0, 28.0]              |                          |             |
| PANSS Negative Score           |                               |                          |             |
| Mean \((SD)\)                  | 16.9 (6.9)                    |                          |             |
| Median [Min, Max]              | 15.0 [8.0, 33.0]              |                          |             |
| PANSS General Score            |                               |                          |             |
| Mean \((SD)\)                  | 30.9 (7.9)                    |                          |             |
| Median [Min, Max]              | 30.0 [20.0, 52.0]             |                          |             |
| CPZ-equivalence                |                               |                          |             |
| Mean \((SD)\)                  | 519.4 (419.3)                 |                          |             |
| Median [Min, Max]              | 392.0 [75.0, 2100.0]          |                          |             |

*Note.* \(p\)-value = probability value, \(SD\)= standard deviation, PANSS= Positive and Negative Syndrome Scale, CPZ-equivalence= chlorpromazine-equivalence. CPZ-equivalence was calculated for all antipsychotics based on the equivalent oral dose of chlorpromazine.